Swedish biopharmaceutical company Immunicum AB (STO:IMMU) has changed its corporate name to Mendus AB, effective immediately, the company announced on Thursday.

This change was approved by shareholders at the Annual General Meeting on 10 May 2022.

According to the company, this rebranding reflects its maturing clinical pipeline and its broader positioning in cancer recurrence immunotherapy.

Mendus will continue trading under the ticker symbol 'IMMU' on Nasdaq Stockholm. The company's new website is http://www.mendus.com.